LEIDEN, Netherlands, Jan. 8, 2025 /PRNewswire/ -- Alesta Therapeutics, a biotechnology company focused on developing transformative small molecule therapies for rare diseases, today announced the ...
SAN FRANCISCO and LEIDEN, Netherlands, Jan. 8, 2025 /PRNewswire/ -- 1cBio, Inc. ("1cBio") an emerging biotech company developing precision medicines for significant unmet needs, and Alesta ...
LEIDEN, The Netherlands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alesta Therapeutics, a biotechnology company focused on developing transformative small-molecule therapies for underserved diseases, provided ...
Alesta Therapeutics BV has identified eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.
Lead program ALE1 for hypophosphatasia (HPP) progressing through the clinic with a Ph1/2a study currently ongoing in healthy volunteers; HPP patients expected to be dosed in H1 2026 Second therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results